Ferring’s Propess® is the first pharmacological treatment for cervical ripening to be approved in Japan for over 20 years
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced that Propess® (dinoprostone) has been approved by the Minister of Health, Labour and Welfare (MHLW) in Japan for initiation of cervical ripening in patients at term (from 37 completed weeks of gestation).1 This is the first time in over 20 years that a pharmacological therapy for cervical ripening has been approved in the country.2 Around 10 per cent of births globally require induction of labour, which may be req ...
